At 6.5% CAGR, the North America Enteral and Parenteral Medical Nutrition Market is projected to be worth US$ 11,030.78 million by 2028, says Business Market Insights

According to Business Market Insights research, the North America enteral and parenteral medical nutrition market was valued at US$ 8,049.98 million in 2023 and is expected to reach US$ 11,030.78 million by 2028, registering a CAGR of 6.5% from 2023 to 2028. Rise in prevalence of gastrointestinal diseases and increasing cases of malnutrition and premature births are the critical factors attributed to the North America enteral and parenteral medical nutrition market expansion.        

Product recalls caused by issues with artwork and packaging are an ongoing problem for many consumer and pharmaceutical companies. The problems can come from several areas, such as non-standardized bills of material, translation mistakes, typos, and poor proofreading, expired digital assets, poor printing quality, third-party artwork suppliers, and printing shops. Malnutrition includes being undernourished, overweight or obese, having inadequate vitamins or minerals, and having a non-communicable disease due to a bad diet. As per World Health Organization (WHO) data, ~1.9 billion adults were overweight or obese, whereas 462 million were underweight in 2021. Additionally, 39 million children under the age of 5 were overweight, 149 million had stunted growth and development due to a chronic lack of nutrient-rich food in their diets, and 45 million were wasted (too thin for height). ~45% of deaths among children aged less than 5 are associated with undernutrition. As per the July 2022 data of the United Nations International Children's Emergency Fund (UNICEF), the prevalence of undernourishment reached 9.3% in 2020 from 8.0% in 2019; it further jumped to 9.8% in 2021. Similarly, as per a study titled “A multi-center survey on hospital malnutrition,” published in 2021, ~33% of hospital patients in the US were either malnourished or at nutritional risk, and nearly 11–45% of patients in hospitals and home care settings in England suffered from malnutrition. Nutritional support delivered through enteral & parenteral means, depending on the need, is an important and appropriate way of treating most malnutrition cases. Thus, the huge burden of malnutrition in children and adults drives the demand for enteral and parenteral nutrition formulae and products.

Preterm birth refers to a baby being born too early, i.e., before the completion of 37 weeks of pregnancy. As per the WHO data published in 2023, ~13.4 million preterm birth (more than 1 in 10 births) were reported worldwide in 2020.   According to the Centers for Disease Control and Prevention (CDC) data, preterm birth in the US accounted for 10% of all births in 2020 and reached 10.5% in 2021, recording a yearly rise of 4%. Per the same source, the rate of preterm birth among African American women (14.8%) was about 50% higher than the rate reported among white or Hispanic women (9.5% and 10.2%, respectively). A large number of premature babies suffer from low weight and undeveloped immunity, which puts their life at risk. Most medical guidelines advise enteral nutrition for supporting the optimal growth of preterm infants if they are unable to drink, suck, swallow, and breathe, also parenteral nutrition are preferred in such babies due to sucking or swallowing difficulties as a complication of an immature birth or due to neuromuscular, heart, or other disorders. Hence, with the high number of preterm births, the demand for enteral and parenteral medical nutrition is on the rise in the North America.

On the contrary, mechanical, gastrointestinal, and metabolic complications associated with enteral and parenteral feeding systems, and limitations related to catheter placement hampers the North America Enteral and Parenteral Medical Nutrition Market.  

Based on indication, the North America enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held 29.9% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$  2,406.72 million. It is projected to garner US$ 3,330.47 million by 2028 to expand at 6.7% CAGR during 2023–2028.

Based on nutrition type, the North America enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 79.0% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 6,356.59 million. It is projected to garner US$ 8,651.86 million by 2028 to expand at 6.4% CAGR during 2023–2028.

Based on form, the North America enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held 53.5% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 4,303.19 million. It is projected to garner US$ 5,917.77 million by 2028 to expand at 6.6% CAGR during 2023–2028.

Based on product type, the North America enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held 57.7% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 4,644.46 million. It is projected to garner US$ 6,419.06 million by 2028 to expand at 6.7% CAGR during 2023–2028.

Based on route of administration, the North America enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held 43.8% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 3,524.29 million. It is projected to garner US$ 4,792.65 million by 2028 to expand at 6.3% CAGR during 2023–2028.

Based on age group, the North America enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held 39.4% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 3,173.56 million. It is projected to garner US$ 4,364.34 million by 2028 to expand at 6.6% CAGR during 2023–2028.

Based on distribution channel, the North America enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held 40.6% share of North America Enteral and Parenteral Medical Nutrition Market in 2023, amassing US$ 3,269.34 million. It is projected to garner US$ 4,430.03 million by 2028 to expand at 6.3% CAGR during 2023–2028.

Based on country, the North America enteral and parenteral medical nutrition market has been categorized into the US, and Canada. Our regional analysis states that the US captured 81.6% share of North America Enteral and Parenteral Medical Nutrition Market in 2023. It was assessed at US$ 6,569.81 million in 2023 and is likely to hit US$ 9,061.03 million by 2028, exhibiting a CAGR of 6.6% during the forecast period.      

Key players operating in the North America enteral and parenteral medical nutrition market are Abbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Medica Nutrition Inc; Medtrition Inc; Nestle SA; Nutricia International BV; and Nutrisens SAS, among others.  

• November 2021, Abbott Launched Similac 360 Total Care to Support the Immune System, Digestive Health and Brain Development. Similac 360 Total Care is the first and only infant formula in the U.S. with a blend of five different HMOs, previously only found together in breast milk. This formula is designed to provide nutrition to support the whole baby’s health and development, including the developing immune system, digestive system and brain.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com